RxDoctor Payments Data

Debbie Raymond

Psychiatric/Mental Health · Arcadia, FLNPI 1336780857

Payments from drug & device makers

$2,583in general payments, 2019–2025

Across 89 payments — averaging $29.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Alpha Cognition USA, Inc.$737
  • Neurocrine Biosciences, Inc.$483
  • Acadia Pharmaceuticals Inc$181
  • Otsuka America Pharmaceutical, Inc.$84

What the payments were for

  • Food & beverage$2,36291%
  • Education$2219%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,583 in reported general payments places this provider in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$224,755
Medicare patients
707
Services billed
2,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine31$286,777
NuedextaDextromethorphan Hbr/Quinidine140$214,475
IngrezzaValbenazine Tosylate19$161,674
NuplazidPimavanserin Tartrate19$100,619
Trazodone Hcl195$3,068
Divalproex Sodium59$2,388
Sertraline Hcl78$1,340
Lorazepam69$1,225
Quetiapine Fumarate50$1,047
Aripiprazole22$617
Duloxetine Hcl13$392
Mirtazapine19$365
Donepezil Hcl15$254
Olanzapine11$220
Clonazepam22$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$1,097$286,77731 claims
Neurocrine Biosciences, Inc.Ingrezza$483$161,67419 claims
Acadia Pharmaceuticals IncNuplazid$181$100,61919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Arcadia

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →